The reaffirmed guidance provides a floor, but the declining adjusted EBITDA and negative FCF signal ongoing transition costs. Watch for Q2 2026 results to confirm whether distributor transitions are truly behind them and if margin expansion materializes as guided. The $63.9M financing inflow (likely debt draw) raises leverage concerns.
Price Chart
Executive Summary
Orthofix reported Q1 2026 pro forma net sales of $196.4M (+2.7% YoY constant currency) and a GAAP net loss of $(20.9)M, or $(0.52) per share, narrowing from a $(53.1)M loss a year ago. The company reaffirmed full-year 2026 guidance of $850M-$860M in net sales and $95M-$98M in adjusted EBITDA, but the quarter showed a 15.2% decline in pro forma adjusted EBITDA to $9.7M and negative free cash flow of $(28.3)M, reflecting ongoing distributor transition costs and margin pressure.
Key Financial Metrics
Key Facts
- Q1 2026 pro forma net sales $196.4M, up 2.7% YoY constant currency vs $189.2M in Q1 2025
- GAAP net loss $(20.9)M vs $(53.1)M in Q1 2025; GAAP EPS $(0.52) vs $(1.35)
- Pro forma adjusted EBITDA $9.7M (4.9% of sales) vs $11.4M (6.0% of sales) in Q1 2025, down 15.2%
- Free cash flow negative $(28.3)M vs $(25.1)M in Q1 2025
- Full-year 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF expected
- Global Spine Fixation grew 6% YoY constant currency; Therapeutic Solutions +5%; Limb Reconstruction +3%
- Cash and restricted cash $120.9M at quarter-end, up from $85.1M at Dec 2025 due to financing activities
- Long-term debt increased to $221.3M from $157.4M at Dec 2025
Financial Impact
Pro forma net sales grew $7.2M YoY, but adjusted EBITDA declined $1.7M; free cash flow worsened by $3.2M
Risk Factors
- Distributor transition headwinds may persist longer than guided, pressuring near-term revenue growth
- Adjusted EBITDA margin compression (down 110 bps YoY) could delay path to positive FCF
- Long-term debt increased 40.6% from Dec 2025, increasing interest expense burden
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204999 |
| Document: ofix-20260505.htm | 0001193125-26-204999 |
| Document: ofix-ex99_2.htm | 0001193125-26-204999 |
| Document: 0001193125-26-204999-index-headers.html | 0001193125-26-204999 |
| Document: 0001193125-26-204999-index.html | 0001193125-26-204999 |
| Document: 0001193125-26-204999.txt | 0001193125-26-204999 |
| 8-K Data (Synthetic) | 0001193125-26-204999 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | Insider Buy | $9.18 $9.74 | ▲ +6.10% | ▲ +5.41% | $9.78 (+6.54%) |
Aug 20, 2026 9w ago | Insider Cluster | $10.01 $8.95 | ▼ −10.59% | ▼ −10.06% | $9.78 (−2.30%) |
Aug 5, 2026 11w ago | 8-K | $10.42 $9.38 | ▼ −9.98% | ▼ −9.38% | $9.78 (−6.14%) |
Jul 2, 2026 16w ago | 8-K | $9.94 $11.79 | ▲ +18.61% | ▲ +19.03% | $9.78 (−1.61%) |
May 21, 2026 22w ago | 8-K | $10.41 $8.90 | ▲ +14.55% | ▲ +14.89% | $9.78 (+6.05%) |
May 5, 2026 25w ago | 8-K | $12.44 $9.71 | ▼ −21.95% | ▼ −26.90% | $9.78 (−21.38%) |
Apr 29, 2026 25w ago | DEFA14A | $11.76 $9.27 | ▼ −21.17% | ▼ −26.40% | $9.78 (−16.84%) |
Apr 9, 2026 28w ago | 8-K | $12.42 $12.19 | ▼ −1.85% | ▼ −9.42% | $9.78 (−21.26%) |
Mar 10, 2026 32w ago | Insider Cluster | $12.27 $12.42 | ▲ +1.22% | ▲ +0.69% | $9.78 (−20.29%) |
Mar 5, 2026 33w ago | Insider Cluster | $12.57 $11.53 | ▲ +8.27% | ▲ +4.49% | $9.78 (+22.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers